Economic Evaluation of Extended-Release Amphetamine (Dyanavel XR) Among Individuals with
Ishveen Chopra1, Jennifer Horng1, Melanie S Krause1
1Tris Pharma, Inc., Monmouth Junction, NJ, USA.
Introduction:
In the treatment of attention-deficit/hyperactivity disorder (ADHD), supplemental use of immediate-release (IR) stimulants can lead to fluctuating plasma levels that impede symptom control and are more prone to diversion. The negative implications of IR stimulant supplementation are broad, leading to extra costs and harm to individuals and society. To quantify the economic impact of IR supplementation from a United States societal perspective, this study evaluated the incremental cost difference between Dyanavel XR and other extended-release (ER) stimulants over a one-year base-case horizon and summarized value using a benefit-cost ratio.
Methods:
As a hypothesis-generating approach, a decision-tree model compared these interventions across direct medical, non-medical, and indirect costs. Analysis was conducted for the general ADHD population and stratified by age group to account for differences in medication use, adherence, and costs. Suboptimal response combined IR supplementation and patient-reported end-of-dose crash, with all inputs drawn from the published literature.
Results:
The average per-person cost for Dyanavel XR was $43,219 versus $51,071 for other ER stimulants, resulting in savings of $7,852 per person over one year. Nationally, Dyanavel XR resulted in $44.6 billion in aggregate savings. The benefit-cost ratio of Dyanavel XR was 12.59, indicating that benefits outweighed the treatment cost; 16.89 in young adults and 0.89 in children. In one-way deterministic sensitivity analysis, Dyanavel XR remained cost-saving, highlighting the robustness of the economic benefit.
Conclusion:
From a United States societal perspective, Dyanavel XR demonstrates an economic advantage over other ER stimulants, with value most pronounced in young adults and lower in children. Dyanavel XR's potential to reduce IR supplementation and end-of-dose crash, thereby mitigating downstream costs, makes it a compelling ADHD treatment option. The model's operational definition of suboptimal response is intended as a pragmatic framework for future research to test its predictive validity for clinical outcomes and quality-of-life measures.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:28Adrenergic Agonists: Mixed-Action Agents
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
01:24CNS Stimulants: Cocaine, Amphetamines and Cannabinoids
01:29Stimulants
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
01:21Drugs Affecting Neurotransmitter Release or Uptake
01:25Adrenergic Agonists: Indirect-Acting Agents
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...